SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Blueprint Medicines Corporation - BPMC

New York, New York--(Newsfile Corp. - July 11, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ: BPMC). Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 7980.

The investigation concerns whether Blueprint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 9, 2022, Blueprint issued a press release disclosing that the Company "plans to update the primary endpoint of the registrational PIONEER trial of AYVAKIT in patients with non-advanced SM, based on a written recommendation from the U.S. Food and Drug Administration (FDA) on statistical considerations ahead of the planned database lock."

On this news, Blueprint's stock price fell $5.73 per share, or 8.88%, to close at $58.77 per share on June 9, 2022.

Then, on June 10, 2022, Citi downgraded Blueprint to Sell from Neutral, opining that "even if the trial succeeds on the primary endpoint, magnitude of benefit will not be enough to support Street projections."

On this new, Blueprint's stock price fell $10.70 per share, or 18.21%, to close at $48.07 per share on June 10, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

Robert S. Willoughby
Pomerantz LLP
888-476-6529 ext. 7980

To view the source version of this press release, please visit